Trial Profile
A Phase I Trial of AR1003 for Sepsis
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 21 Jun 2020
Price :
$35
*
At a glance
- Drugs AR 1003 (Primary)
- Indications Sepsis
- Focus Adverse reactions
- Sponsors AriBio
- 17 Jun 2020 According to an AriBio media release, AR1003 is preparing to enter this Phase 1 study in the United States by early 2021.
- 20 Oct 2016 New trial record
- 01 Jun 2016 According to an AriBio media release, this trial will be conducted in 2017 after granting FDA IND license.